Dr. Reddy's Board Approves FY26 Results, Recommends ₹8 Dividend, Appoints New Directors
Dr. Reddy's Board approved FY26 audited results, reporting Q4FY26 revenues of ₹75,162 million and FY26 revenues of ₹335,933 million. A final dividend of ₹8 per share was recommended. Key appointments include Dr. K P Krishnan (re-appointment) and Mr. Srikanth Velamakanni (appointment) as Independent Directors.
The announcement includes the approval of financial results, dividend recommendation, and significant board/auditor appointments, which are material for investors. The financial performance, despite some headwinds, and strategic personnel changes warrant a medium impact.
The results show a decline in Q4 revenue YoY due to specific factors like lower lenalidomide sales and one-off adjustments. While the full-year revenue saw growth, the mixed performance and the impact of one-off items lead to a neutral sentiment.
Dr. Reddy's Laboratories Limited announced the outcome of its Board Meeting held on May 12, 2026. The Board approved the audited financial results for the quarter and financial year ended March 31, 2026, including consolidated and standalone financial statements prepared under IFRS and Ind AS, along with the auditors' reports.
The Board recommended a final dividend of ₹8 per equity share for the financial year 2025-26, subject to shareholder approval at the ensuing Annual General Meeting (AGM). The record date for this dividend has been fixed as July 10, 2026.
Furthermore, the company's 42nd AGM is scheduled to be convened on Thursday, July 23, 2026. The Board also approved key appointments and re-appointments: Dr. K P Krishnan was re-appointed as an Independent Director for a second term from January 7, 2027, to January 6, 2032. Mr. Srikanth Velamakanni was appointed as an Additional Director, categorized as an Independent Director, for a term of five years from July 1, 2026, to June 30, 2031. M/s Deloitte Haskins & Sells, LLP, Chartered Accountants, were appointed as Statutory Auditors for a term of five years commencing from the conclusion of the 42nd AGM. M/s Sagar & Associates were re-appointed as Cost Auditors for the Financial Year 2026-27. Additionally, Mr. Sandeep Khandelwal was elevated to Senior Management Personnel and inducted as a member of the Management Council, effective May 12, 2026.
The financial results for Q4FY26 showed revenues of ₹75,162 million, a decrease of 11.6% YoY, and profit after tax attributable to equity holders of ₹2,201 million. The full year FY26 revenues were ₹335,933 million, an increase of 3.2% YoY, with a profit after tax of ₹42,850 million. The company highlighted that the performance reflected the impact of lower lenalidomide sales and several one-off events, including a Shelf Stock Adjustment, impairment of assets, and provisions related to VAT liability. Management expressed a focus on strengthening the base business, improving margins, and building long-term franchises.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.